livebaccaratonline| Microcore Biotech (688321.SH): Application for the III clinical trial of cidabenide in the treatment of colorectal cancer accepted

Glonghui May 12 丨 Microchip Biology (688321)(688321livebaccaratonline.SH) announced that the company recently received a certificate from the Center for Drug Evaluation of the State Food and Drug Administration (known as the "Center for Drug Evaluation of the State Food and Drug Administration")livebaccaratonlineThe "Acceptance Notice" for the registration clinical trial of domestically produced drugs, a randomized, open-label, controlled, multi-center, Phase III clinical trial of cidabenamide combined with sintilumab and bevacizumab for the treatment of advanced microsatellite stabilization or complete mismatch repair (MSS/pMMR) colorectal cancer that failed ≥2 lines of standard treatment was accepted by the Center for Drug Evaluation of the State Food and Drug Administration.

Tags:

Prev: familyfeudtelevisionshow| CICC Lingnan received an overweight rating from Guosen Securities, and rising metal prices will increase profits in the mining sector.
Next: 1billionfreewsopchips| Lianhua Supermarket (00980.HK): It plans to issue no more than 360 million new domestic shares to Bailian Group to raise approximately 360 million yuan